Aileron Therapeutics Statistics
Share Statistics
Aileron Therapeutics has 21.67M
shares outstanding. The number of shares has increased by 0.35%
in one year.
| Shares Outstanding | 21.67M |
| Shares Change (YoY) | 0.35% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 20 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 141.21K, so 0.65% of the outstanding
shares have been sold short.
| Short Interest | 141.21K |
| Short % of Shares Out | 0.65% |
| Short % of Float | 0.65% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.89 and the forward
PE ratio is -1.19.
Aileron Therapeutics's PEG ratio is
0.02.
| PE Ratio | -0.89 |
| Forward PE | -1.19 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 2.04 |
| P/FCF Ratio | -0.71 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Aileron Therapeutics has an Enterprise Value (EV) of -3.24M.
| EV / Sales | 0 |
| EV / EBITDA | 0.21 |
| EV / EBIT | 0.16 |
| EV / FCF | 0.16 |
Financial Position
The company has a current ratio of 4.17,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.17 |
| Quick Ratio | 4.17 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -228.43% and Return on Invested Capital is -16.01%.
| Return on Equity | -228.43% |
| Return on Assets | -14.84% |
| Return on Invested Capital | -16.01% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,048,800 |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -57.2% in the
last 52 weeks. The beta is 2.34, so Aileron Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.34 |
| 52-Week Price Change | -57.2% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 2.94 |
| Relative Strength Index (RSI) | 46.58 |
| Average Volume (20 Days) | 101,120 |
Income Statement
| Revenue | n/a |
| Gross Profit | -119K |
| Operating Income | -16.28M |
| Net Income | -15.73M |
| EBITDA | -15.61M |
| EBIT | -15.73M |
| Earnings Per Share (EPS) | -3.42 |
Full Income StatementBalance Sheet
The company has 17.31M in cash and 48K in
debt, giving a net cash position of 17.27M.
| Cash & Cash Equivalents | 17.31M |
| Total Debt | 48K |
| Net Cash | 17.27M |
| Retained Earnings | -288.52M |
| Total Assets | 104.22M |
| Working Capital | 13.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -19.81M
and capital expenditures 0, giving a free cash flow of -19.81M.
| Operating Cash Flow | -19.81M |
| Capital Expenditures | n/a |
| Free Cash Flow | -19.81M |
| FCF Per Share | -4.31 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
